Zentalis Pharmaceuticals (ZNTL) Files DEF 14A for April 28 Meeting

Zentalis Pharmaceuticals (ZNTL) has filed a DEF 14A with the SEC ahead of its shareholder meeting scheduled for April 28. The filing typically includes details about proposals and issues to be voted on by shareholders. This meeting can significantly influence corporate governance and strategic decisions within the company. The event is part of Zentalis’ ongoing efforts to engage its investors and align on future directives.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.